[The pharmacological strategy of overcoming the phenotype of the multiple pharmacoresistance of non-small-cell lung cancer].

The authors discuss literature data and the results of their own many-year research into molecular markers of multiple pharmacoresistance associated with the function of ABC-transporters (MDRABC) from the point of view of their clinical significance. They consider the evolution of views on the mechanism of functioning and intracellular localization of ABC-transporters in normal and tumoral cells, in particular, the role of these transport proteins in the protection of nuclear targets from toxic agents, including antitumoral preparations. By the example of non-small-cell lung cancer (NSCLC) the authors critically analyze the reasons why data on the frequency of ABC-transporters expression in human solid tumors and on their prognostic value are inconsistent. The article contains a detailed analysis of the results of the authors' own research into the activity of ABC-transporters in NSCLC, in which the frequency of expression and co-expression of different transport proteins (including Pgp and MRP) is defined and new characteristics and mechanisms of the regulation of the functioning of MDRABC molecular markers are revealed. A methodical approach to routine characterization of MDRABC phenotype in NSCLC is offered. The main directions of pharmacological strategy of overcoming the multiple pharmacoresistance of NSCLC are formulated.